TERN Company Profile and Key Details

TERN has shown sold momentum, gaining 7.24% over the past week and 334.96% over the past quarter, though year-to-date performance is down -9.46%. Short-term trend indicators are mixed aligned (SMA20 9.01%, SMA50 7.5%, SMA200 144.04%). The stock’s 14-day RSI is 65.11 (firm momentum), while the ATR of 2.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.26% below its high and over 2118.77% above its low. Average 10-day trading volume of 1.76 million shares is below the 3-month average of 2.81 million, indicating normal recent market interest.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) closed at $41.38 USD, losing -$0.07 (-0.17%) from the previous close of $41.45. The stock is currently mid-range between its 52-week high and low $1.86 and $48.26. With a market capitalization of about $3.73 billion, Terns Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.28). Key stats such as the average daily volume over the past year has been around 3.03 million shares, volume is running light vs its 52-week average. Headquartered in Foster City, CA, Terns Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Amy L. Burroughs, the company employs approximately 59 people and listed since February 05, 2021. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

Terns Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.01. This means the shares are trading above this model’s fair value.

Terns Pharmaceuticals, Inc. has 87.51 million shares outstanding. The public float is 57.16 million shares, elevated short interest at 8.14% of float. This equals 7.12 million shares. The short ratio is 6.3 days. Institutional investors hold 82.79% of the float. Insiders own 0.24%. Vivo Capital Surplus Fund VIII, L.P. holds 3.58 million shares, Flynn James E has 2.38 million shares and ORBIMED ADVISORS LLC has 755.64 thousand shares. Over the past six months, insider transactions show net selling. They sold 109.36 thousand shares across 6 transactions.

Terns Pharmaceuticals, Inc. generated EPS of -$1.03 over the past year. Five-year average earnings growth is 16.38%. Wall Street analysts project EPS growth of -8.32% annually over the next five years. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.29. Next year's EPS is expected at -$4.08. Analyst sentiment is bullish. Analyst rating data shows there are 16 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $7.44. The high target offers 45.0% upside. The low target suggests -82.02% downside. The mean target is $34.24. This offers -17.25% upside. Terns Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 10, 2025, missed forecasts by -10.0%. The prior quarter beat by -7.14%. Over the last six quarters, Apple has recorded several small beats. These include -11.43% in August 05, 2024.

Our AI price prediction model suggests that Terns Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.42%, with price expected at $44.45 by March 11, 2026, within a range of $43.06 to $45.87 3-Month Outlook: Projected rise of 9.57%, reaching $45.34 by May 25, 2026, with a range of $45.01 to $45.67. 1-Year Outlook: Projected gain of 10.42%, with price at $45.69 by February 25, 2027, within a range of $42.13 to $48.80.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) shares are flat -9.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Terns Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -40.36. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $23.73, suggesting -42.65% downside. Our AI forecast model points to short-term strength (7.42% over two weeks), a medium-term rise (9.57% over three months), and a longer-term gain (10.42% over one year), with expected trading ranges indicating moderate volatility.

Terns Pharmaceuticals, Inc. trades at a P/E ratio of -40.36, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 13.42 reflecting a rich premium to book value. The P/FCF stands at -48.2, also below market averages. Compared to sector medians, Terns Pharmaceuticals, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.